At Bao Pharmaceutical, based on the understanding of the unique tissue structure of the subcutaneous space, we break through the limitations of subcutaneous drug delivery in the dermis and expand the application of new drug delivery technology.

As a new type of drug delivery technology, subcutaneous drug delivery can be combined with chemical drugs, biological drugs and other types of therapeutic drugs to bring patients a more convenient, more comfortable and safer drug experience.

At Bao Pharmaceutical, we are dedicated to developing clinical solutions for pathogenic IgG-mediated diseases that currently lack effective treatments. We strive to address the clinical needs of patients with various autoimmune diseases (Ads) including rare diseases, certain subtype of cancer and organ transplantation.

We are continuously expanding the applications of recombinant human IgG-degrading enzymes to seek breakthrough for refractory autoimmune diseases.

At Bao Pharmaceutical, we have upgrade the chymotrypsin product by replacing animal organ extraction with genetic engineering technology, offering better safety, quality, and supply of recombinant human protein.

Chymotrypsin is a protease that rapidly breaks down proteins, liquefies pus, and necrotic tissue. It is widely used in over a dozen departments including respiratory, surgical, otolaryngological, obstetric, pediatric, dental, ophthalmic, dermatological, gastrointestinal, and anorectal surgery.